Infertility Clinical Trial
Official title:
Will Piezo-ICSI Increase Fertilization Rates Compared to Conventional ICSI? A Prospective Randomized Sibling Study.
NCT number | NCT04669652 |
Other study ID # | 4026 - EPI |
Secondary ID | |
Status | Suspended |
Phase | N/A |
First received | |
Last updated | |
Start date | September 2023 |
Est. completion date | October 2024 |
Verified date | October 2022 |
Source | Vitrolife |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Intracytoplasmic sperm injection (ICSI) has successfully been used to treat both severe male infertility and fertilization failure since its introduction in the early 1990´s. During the procedure a single sperm is injected into the cytoplasm of an oocyte to achieve fertilization. This technique is intrusive, has a relatively long learning curve and variable operator performance. A new injection technique called piezo-ICSI has recently been introduced. During piezo-ICSI, a piezo-electric effect is generated through the conversion of electric energy to mechanical energy. This causes a smooth movement of the injection pipette, which allows for steady, controlled microinjections with less psychical stress applied on the oocytes than by the conventional technique. A recent analysis, based on data from 9 different studies comparing conventional ICSI and piezo-ICSI (17500 cases), showed a benefit of piezo. Unfortunately, proper randomized trials are missing from this analysis. The proposed study is a randomized controlled study carried out at two private IVF clinics. Eligible participants are patients undergoing ICSI treatment, with a minimum of 6 oocytes. The participants will act as their own controls, with their oocytes randomly and equally divided between injection by the investigated and the conventional technique. Whether piezo-ICSI is associated with improved success rates or reduction in adverse outcomes is at present unclear. Patients with fragile oocytes may benefit more from piezo-ICSI. In patients above 35 years, piezo-ICSI has been associated with a lower oocyte degeneration rate and an increased blastocyst rate. The aim of the study is to investigate whether the piezo-ICSI technique will result in more oocytes becoming normally fertilized compared to conventional ICSI. Another proposed benefit of piezo-ICSI lies in the standardization and simplification of the ICSI procedure. Making the injection procedure more independent of operator skill may result in a more robust and predictable laboratory output.
Status | Suspended |
Enrollment | 265 |
Est. completion date | October 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: 1. Patients receiving controlled ovarian stimulation with gonadotrophins needing ICSI for fertilizing oocytes. 2. Availability of at least six mature oocytes (MII) after oocyte pick-up. 3. Planned blastocyst culture. Exclusion Criteria: 1. Intention to perform any form of preimplantation genetic testing 2. The use of IMSI or polarized light in the ICSI process 3. The use of assisted hatching prior to randomization. 4. Surgical sperm retrieval (SSR) patients. 5. Previous participation in this RCT 6. Concurrent participation in another investigation that can affect the primary outcome of this study. 7. Sperm sample with <0.1million/ml or motility of <2% after preparation. 8. Fertility preservation cycles. 9. If a day 2-4 transfer is planned 10. Use of vitrified oocytes. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Nurture Fertility (TFP) | Nottingham | |
United Kingdom | Oxford Fertility (TFP) | Oxford |
Lead Sponsor | Collaborator |
---|---|
Vitrolife |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fertilization rate | Number of normally fertilized oocytes per injected oocytes | Oocytes will be observed over a period of 26 hours after the intervention | |
Secondary | Percentage of degenerated oocytes | Number of oocytes that have degenerated after the procedure | Oocytes will be observed over a period of 26 hours after the intervention | |
Secondary | Percentage of 0 PN oocytes | Number of oocytes not fertilized (0 PN) after the procedure. | Oocytes will be observed over a period of 26 hours after the intervention | |
Secondary | Percentage of 1 PN oocytes. | Number of oocytes fertilized with one pronuclei (1 PN) after the procedure. | Oocytes will be observed over a period of 26 hours after the intervention | |
Secondary | Percentage of >2PN oocytes. | Number of oocytes fertilized with more than 2 pronuclei (>2PN) after the procedure. | Oocytes will be observed over a period of 26 hours after the intervention | |
Secondary | Differences in KID scores. | Embryo development will be analysed using a mathematical models called KID (0-10 scale). | Embryos will be observed over a period of 6 days after the procedure | |
Secondary | Differences in iDA scores. | Embryo development will be analyzed using a artificial intelligence model, called iDA (0-10 scale). | Embryos will be observed over a period of 6 days after the procedure | |
Secondary | Blastocyst rate (number of grade 3 or higher). | Number of blastocysts with a morphological score of grade 3 or higher. | Embryos will be observed over a period of 6 days after the procedure | |
Secondary | Percentage of cryopreserved blastocysts on day 5 and 6. | Number of blastocysts cryopreserved on day 5 and day 6. | Embryos will be observed over a period of 6 days after the procedure | |
Secondary | 8. Utilization rate (Number of transferred and cryopreserved blastocysts). Utilization rate | Number of transferred and cryopreserved blastocysts | Embryos will be observed over a period of 6 days after the procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A |